Calliditas Therapeutics AB (publ) operates as a clinical-stage biopharmaceutical entity, committed to identifying, advancing, and commercializing therapeutic products. Its primary focus lies in developing treatments for rare (orphan) conditions, with a particular emphasis on disorders impacting the renal and hepatic systems. The company markets Nefecon, an orally administered formulation of budesonide, which functions as an immunosuppressive agent designed to address immunoglobulin A nephropathy, an autoimmune kidney disease. Its flagship investigational product is Setanaxib, a NOX inhibitor. Setanaxib is currently undergoing Phase 2b/3 clinical trials for primary biliary cholangitis. Furthermore, it is being evaluated in Phase 2 studies for various other indications, including squamous cell carcinoma of the head and neck, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Calliditas's pipeline also includes Budenofalk 3 mg oral capsules, which are under development for the treatment of autoimmune hepatitis. The company was established in 2004 and has its corporate headquarters located in Stockholm, Sweden.